<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03583593</url>
  </required_header>
  <id_info>
    <org_study_id>DIAMEL-DIABETICFOOT</org_study_id>
    <nct_id>NCT03583593</nct_id>
  </id_info>
  <brief_title>Evaluation of DIAMEL® Combined With Insulin in Diabetic Foot Ulcer</brief_title>
  <official_title>Evaluation of Nutritional Supplement DIAMEL® Combined With Insulin in Diabetic Foot Ulcer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalysis SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catalysis SL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic foot syndrome is one of the most frequent complications in type 2 diabetic patients.
      The present work is carried out with the objective of evaluating the use of DIamel combined
      with insulin in diabetic foot ulcers. Method. Phase II clinical trial. A study group was
      created that receives the active product and another control group that receives a placebo.
      Double-blind study with a monthly follow-up for the first 6 months and then quarterly until
      the end of 1 year. Complementary tests are performed every 6 months to evaluate metabolic,
      lipid and renal function control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2014</start_date>
  <completion_date type="Actual">November 30, 2017</completion_date>
  <primary_completion_date type="Actual">November 12, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>It is a double blind study, that is, neither the researcher nor the patient knows if he takes placebo or the active tablet.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time of healing</measure>
    <time_frame>1 year</time_frame>
    <description>The most important outcome measure is to evaluate the early healing of diabetic foot ulcers with the shape and improvements of the foot ulcers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemic control</measure>
    <time_frame>1 year</time_frame>
    <description>Glucose measures with blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipidic control</measure>
    <time_frame>1 year</time_frame>
    <description>Triglycerides and cholesterol levels with blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass control</measure>
    <time_frame>1 year</time_frame>
    <description>Body mass test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function control</measure>
    <time_frame>1 year</time_frame>
    <description>Renal function measures by Creatinine Clearance Blood Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin control</measure>
    <time_frame>1 year</time_frame>
    <description>Insulin levels measured by the Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) and insulin sensitivity (%S), as percentages of a normal reference population</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <condition>Diabetic Foot</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>DIAMEL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study group that receives the active product.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group receiving double-blind placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>DIAMEL</intervention_name>
    <description>Diamel is administered 6 capsules a day divided into three doses that are ingested before each meal.</description>
    <arm_group_label>DIAMEL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is administered 6 capsules a day divided into three doses that are ingested before each meal.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (% B)
             and insulin sensitivity (% S), as percentages of a normal reference population

        Exclusion Criteria:

          -  Manifestation of hypersensitivity to any component of the product

          -  Uncooperative patients

          -  Severe infection

          -  Debilitating diseases

          -  Steroid treatment

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institute of Endocrinology</name>
      <address>
        <city>Vedado</city>
        <state>Havana</state>
        <zip>10400</zip>
        <country>Cuba</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cuba</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 15, 2018</study_first_submitted>
  <study_first_submitted_qc>June 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <last_update_submitted>June 28, 2018</last_update_submitted>
  <last_update_submitted_qc>June 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Insulin</keyword>
  <keyword>Diabetic Foot</keyword>
  <keyword>Nutritional supplement</keyword>
  <keyword>Diamel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

